Search research articles
Contact Us
Filters
Showing results (41-50 of 218) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2014
Reply to M. Perier-Muzet et al
Lisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2013
Conjunctival melanomas harbor BRAF and NRAS mutations--response
Klaus G Griewank, Henrike Westekemper, Bastian Schilling, et al.
Plos One
|
November 22, 2013
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma
Klaus G Griewank, Rajmohan Murali, Bastian Schilling, et al.
Cancer Immunology, Immunotherapy : CII
|
April 18, 2019
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series
Selma Ugurel, Ivelina Spassova, Jonas Wohlfarth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma
Selma Ugurel, Felix Kiecker, Stefan Fröhling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
April 20, 2026
Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI)
Venja Musche, Theresa Schadendorf, Adam Schweda, et al.
Cancers
|
March 11, 2023
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Martin Salzmann, Alexander Wald, Henner Stege, et al.
ESMO Open
|
June 25, 2019
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.
Journal of Clinical Medicine
|
July 8, 2020
ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry
Julia Pohl, Raluca-Ileana Mincu, Simone Maria Mrotzek, et al.
Cancers
|
December 11, 2025
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. <i>Cancers</i> 2023, <i>15</i>, 3448
Jessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
Page
of 22
Search research articles
Search
Showing results (41-50 of 218) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2014
Reply to M. Perier-Muzet et al
Lisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2013
Conjunctival melanomas harbor BRAF and NRAS mutations--response
Klaus G Griewank, Henrike Westekemper, Bastian Schilling, et al.
Plos One
|
November 22, 2013
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma
Klaus G Griewank, Rajmohan Murali, Bastian Schilling, et al.
Cancer Immunology, Immunotherapy : CII
|
April 18, 2019
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series
Selma Ugurel, Ivelina Spassova, Jonas Wohlfarth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma
Selma Ugurel, Felix Kiecker, Stefan Fröhling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
April 20, 2026
Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI)
Venja Musche, Theresa Schadendorf, Adam Schweda, et al.
Cancers
|
March 11, 2023
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Martin Salzmann, Alexander Wald, Henner Stege, et al.
ESMO Open
|
June 25, 2019
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.
Journal of Clinical Medicine
|
July 8, 2020
ECG Changes in Melanoma Patients Undergoing Cancer Therapy-Data From the ECoR Registry
Julia Pohl, Raluca-Ileana Mincu, Simone Maria Mrotzek, et al.
Cancers
|
December 11, 2025
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. <i>Cancers</i> 2023, <i>15</i>, 3448
Jessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.
Page
of 22